Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy found that an oral bacterium commonly associated with periodontal disease can promote breast cancer initiation, tumor growth and spread by inducing DNA damage and altering cancer cell behavior.

What if the earliest signs of skin cancer could be identified sooner — before a dermatology appointment?

Researchers at the University of Missouri are exploring how artificial intelligence could help detect melanoma — the most dangerous form of skin cancer — by evaluating images of suspicious skin abnormalities.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease in the Western world, driven by obesity, insulin resistance, and systemic inflammation. Its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), can culminate in cirrhosis and hepatocellular carcinoma (HCC). While lifestyle modification remains central to MASLD management, there is growing interest in pharmacological interventions, particularly nutrient-stimulated hormone-based therapies (NuSHs), such as GLP-1 receptor agonists. NuSHs exert metabolic and anti-inflammatory effects primarily via weight loss and improved insulin sensitivity. Emerging clinical data support their efficacy in resolving MASH without worsening fibrosis. However, benefits in cirrhotic patients are less evident, suggesting greater utility in early intervention. Observational studies and clinical trials suggest a reduction in liver-related morbidity with GLP-1 receptor agonist use, though fibrosis regression remains inconsistent. Preclinical models indicate that NuSHs may also reduce MASH-related HCC incidence and tumor burden, likely through systemic metabolic improvements rather than direct antineoplastic action. Observational human data following bariatric surgery reinforce this link, suggesting that weight loss itself plays a key preventive role. Herein, we propose that NuSHs are promising candidates for MASH-related HCC prevention. We provide mechanistic suggestions for how this may occur. Furthermore, incorporating NuSHs into the post-locoregional treatment pathway for HCC may delay the need for systemic anti-cancer therapies, improve immunotherapy synergy and transplant eligibility, and even slow disease progression through reversal of carcinogenic drivers. Future studies are needed to target oncological endpoints and clarify immunometabolic mechanisms to guide the integration of NuSHs into MASLD treatment algorithms.

This study introduces a dual-scale CapCell microscope, a novel imaging system to dynamically visualize metabolic and vascular adaptations in vivo. The platform reveals subregional features associated with treatment that are often missed by bulk analyses.

At Frontiers Science House, SPARK Microgravity GmbH revealed plans to build Europe’s first dedicated commercial orbital cancer lab. The lab will accelerate the path from discovery to therapy. In microgravity, researchers can run experiments that are impossible on Earth – including 3D tumor growth and revealing new drug targets.

In a multi-institutional study published today in Nature Nanotechnology, researchers from The University of Texas MD Anderson Cancer Center reported that engineered bispecific nanobodies successfully strengthened mucosal defenses in the respiratory tract, improving protection against influenza infection and reducing SARS-CoV-2 transmission in vivo.

Mitotane is the only FDA- and EMA-approved drug for adrenocortical carcinoma, acting through disruption of cholesterol metabolism and steroidogenic enzymes. This review summarizes its mechanisms, clinical efficacy, therapeutic drug monitoring, and adverse effect management, emphasizing the importance of the therapeutic window (14–20 mg/L) for optimized clinical outcomes.